Resolution Biosciences
The firm is expanding its lab capabilities and leveraging its test development reputation to form partnerships early in the drug development process.
Agilent Technologies to Acquire Liquid Biopsy Firm Resolution Bioscience for up to $695M
Under the deal, expected to close in April, Agilent will pay $550 million in cash on closing and up to an additional $145 million based on future milestones.
Resolution Bioscience, Mirati Therapeutics Sign Companion Diagnostic Agreement
The firms will use Resolution's ctDx liquid biopsy technology to find non-small cell lung cancer patients who may benefit from Mirati's KRAS G12C inhibitor therapy.
Nonprofit Friends of Cancer Research Launches Public-Private HRD Harmonization Project
The consortium aims to harmonize the use of homologous recombination deficiency as a biomarker to guide certain treatment types in cancer patients.
A study presented at the AACR meeting showed that Resolution's ctDx-Lung assay reported more oncogenic fusions than Guardant360 in NSCLC patients.